^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    T-Plex-200-A0201/204-A0201

    i
    Other names: T-Plex-200-A0201/204-A0201, multiplexed TCR-T, TSC-204-A0201 + TSC-200-A0201
    Associations

    News

    Trials
    Company:
    TSCan Therap
    Drug class:
    TCR modulator
    Related drugs:
    Associations

    News

    Trials
    11ms
    A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, TScan Therapeutics, Inc. | Initiation date: Nov 2023 --> Feb 2024
    Trial initiation date • IO biomarker • Pan tumor • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    HLA-A*02
    |
    T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
    1year
    A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, TScan Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Pan tumor • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    HLA-A*02
    |
    T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
    1year
    Overcoming tumor heterogeneity – Clinical trial assays to prospectively assign patients customized multiplexed TCR-T cell therapy in Phase 1 (SITC 2023)
    Importantly, HLA-A/B/C alleles were almost always lost together, indicating that HLA loss most frequently occurs through haplotype loss, informing a strategy to direct multiplexed TCR-T to the remaining HLA haplotype. Conclusions Overall, these data highlight the importance of a multiplexed TCR-T cell therapy targeting various intact tumor antigens presented on intact HLA alleles in order to effectively address solid tumors.
    P1 data • Clinical
    |
    HLA-B (Major Histocompatibility Complex, Class I, B) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    PRAME expression
    |
    Tempus HLA-LOH assay
    |
    T-Plex-200-A0201/204-A0201
    over1year
    A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, TScan Therapeutics, Inc.
    New P1 trial • Pan tumor • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    HLA-A*02
    |
    T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702